Clinical Trial

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 6 locations 2026-03-31
Trial Details
NCT Number NCT07305818
Lead Sponsor Merida Biosciences
Conditions Graves Disease
Enrollment 100 participants
Start Date 2025-12-19
Primary Completion 2028-07-24 (estimated)
Study Completion 2028-07-24 (estimated)
Updated on ClinicalTrials.gov 2026-08-03